

**Evaluation of
Normal Tissue Complication Probability
and Risk of Second Primary Cancer
in Prostate Radiotherapy**

Rungdham Takam

*Thesis submitted for the degree of
Doctor of Philosophy*

in

*The School of Chemistry and Physics,
The University of Adelaide*

Supervisors

A/Prof. Eva Bezak

Prof. Eric E. Yeoh

Dr. Guilin Liu



April 2010

Bibliography

1. Abdel-Wahab M, Reis IM, Hamilton K. Second primary cancer after radiotherapy for prostate cancer - a SEER analysis of brachytherapy versus external beam radiotherapy. *International Journal of Radiation Oncology Biology Physics* 2008; **72**: 58 - 68.
2. AIHW, AACR. Cancer in Australia: an overview, 2008. Canberra: Australian Institute of Health and Welfare & Australasian Association of Cancer Registries; 2008.
3. Akimoto T, Katoh H, Noda S-E, *et al.* Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: 472 - 478.
4. Akimoto T, Muramatsu H, Takahashi M, *et al.* Rectal bleeding after hypofractionated radiotherapy for prostate cancer: Correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. *International Journal of Radiation Oncology Biology Physics* 2004; **60**: 1033 - 1039.
5. Amer AM, Mott J, Mackay RI, *et al.* Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2003; **56**: 199 - 207.
6. Anderson CM, Mahadevan A, Reddy C, *et al.* External beam radiation dose response and toxicity in low-risk prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: S318.
7. Aoyama H, Westerly DC, Mackie TR, *et al.* Integral radiation dose to normal structures with conformal external beam radiation. *International Journal of Radiation Oncology Biology Physics* 2006; **64**: 962 - 967.

8. Ares C, Popowski Y, Molla M, *et al.* Hypofractionated boost in prostate cancer radiotherapy as part of two different dose escalation strategies, HDR brachytherapy or IMRT: A late rectal toxicity assessment. *International Journal of Radiation Oncology Biology Physics* 2004; **60**: S477 - S478.
9. Ashman JB, Zelefsky MJ, Hunter MS, *et al.* Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: 765 - 771.
10. Astrom L, Pedersen D, Mercke C, *et al.* Long-term outcome of high dose rate brachytherapy in radiotherapy for localized prostate cancer. *Radiotherapy and Oncology* 2005; **74**: 157 - 161.
11. Aus G, Abbou CC, Bolla M, *et al.* EAU guidelines on prostate cancer. *European Urology* 2005; **48**: 546 - 551.
12. Barendsen GW. Dose fractionation, dose rate and isoeffect relationships for normal tissue response. *International Journal of Radiation Oncology Biology Physics* 1982; **8**: 188 - 197.
13. Barquero R, Mendez R, Iniguez MP, *et al.* Thermoluminescence measurements of neutron dose around a medical linac. *Radiation Protection Dosimetry* 2002; **101**: 493 - 496.
14. Battermann JJ, Boon TA, Moerland MA. Results of permanent prostate brachytherapy, 13 years of experience at a single institution. *Radiotherapy and Oncology* 2004; **71**: 23 - 28.
15. Baxter NN, Tepper JE, Durham SB, *et al.* Increased risk of rectal cancer after prostate radiation: a population-based study. *Gastroenterology* 2005; **128**: 819 - 824.
16. Begg CB, Riedel ER, Bach PB, *et al.* Variations in morbidity after radical prostatectomy. *The New England Journal of Medicine* 2002; **346**: 1138 - 1144.
17. Ben-Amar G, Ben-Shachar B, Oster L, *et al.* Investigation of the glow peak parameters, reusability and dosimetric precision of LiF:Mg,Cu,P at high heating rate up to 20 K.s⁻¹. *Radiation Protection Dosimetry* 1999; **84**: 235 - 238.

18. Bentzen SM. Dose-response relationships in radiotherapy. In: Steel GG, editor. *Basic Clinical Radiobiology*. London: Arnold Publishers; 2002. pp. 94 - 104.
19. Beyer DC, Brachman DG. Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy. *Radiotherapy and Oncology* 2000; **57**: 263 - 267.
20. Bishop DT. The epidemiology of prostate cancer. In: Abel PD, Lalani E-N, editors. *Prostate cancer: clinical and scientific aspects - bridging the gap*. London: Imperial College Press; 2003.
21. Blasko JC, Grimm PD, Sylvester JE, *et al*. Palladium-103 brachytherapy for prostate carcinoma. *International Journal of Radiation Oncology Biology Physics* 2000; **46**: 839 - 850.
22. Bonta DV, Fontenia E, Lu Y, *et al*. A variable critical-volume model for normal tissue complication probability. *Medical Physics* 2001; **28**: 1338 - 1343.
23. Boon SN. Dosimetry and quality control of scanning proton beams. Faculty of Mathematics and Natural sciences. Vol Ph.D. Groningen, Netherland: University of Groningen; 1998. p. 169.
24. Borghede G, Hedelin H. Radiotherapy of localised prostate cancer. Analysis of late treatment complications: a prospective study. *Radiotherapy and Oncology* 1997; **43**: 139 - 146.
25. Boyea G, Martinez A, Wallace M, *et al*. High dose rate (HDR) prostate boost brachytherapy: A comparison of acute and chronic toxicities between three dose escalation groups. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: S188.
26. Brabbins D, Martinez A, Yan D, *et al*. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: Analysis of chronic toxicity. *International Journal of Radiation Oncology Biology Physics* 2005; **61**: 400 - 408.
27. Brenner DJ. Toward optional external-beam fractionation for prostate cancer.

- International Journal of Radiation Oncology Biology Physics* 2000; **48**: 315 - 316.
28. Brenner DJ. Hypofractionation for prostate cancer radiotherapy - what are the issues? *International Journal of Radiation Oncology Biology Physics* 2003; **57**: 912 - 914.
 29. Brenner DJ. Induced second cancers after prostate cancer radiotherapy: no cause for concern? *International Journal of Radiation Oncology Biology Physics* 2006; **65**: 637 - 639.
 30. Brenner DJ, Curtis RE, Hall EJ, *et al.* Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. *Cancer* 2000; **88**: 398 - 406.
 31. Brenner DJ, Martinez AA, Edmundson GK, *et al.* Direct evidence that prostate tumors show high sensitivity to fractionation (low α / β ratio), similar to late-responding normal tissue. *International Journal of Radiation Oncology Biology Physics* 2002; **52**: 6 - 13.
 32. Buffa FM, Fenwick JD, Nahum AE. An analysis of the relationship between radiosensitivity and volume effects in tumor control probability modeling. *Medical Physics* 2000; **27**: 1258 - 1265.
 33. Burman C, Kutcher GJ, Emami B, *et al.* Fitting of normal tissue tolerance data to an analytic function. *International Journal of Radiation Oncology Biology Physics* 1991; **21**: 123 - 135.
 34. Butler W, Merrick G, Wallner K, *et al.* Prostate brachytherapy-induced urethral stricture. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: S299.
 35. Butson MJ, Cheung T, Yu PKN. Peripheral dose measurement with a MOSFET detector. *Applied Radiation and Isotopes* 2005; **62**: 631 - 634.
 36. Cahan WG, Woodward HQ, Higgenbotham NL, *et al.* Sarcoma arising in irradiated bone: Report of eleven cases. *Cancer* 1948; **1**: 382 - 384.
 37. Carinou E, Stamatelatos IE, Kamenopoulou V, *et al.* An MCNP-based model for the evaluation of the photoneutron dose in high energy medical electron

- accelerators. *Physica Medica* 2005; **21**: 95 - 99.
38. Cember H. Chapter 5. Interaction of radiation with matter. In: Introduction to health physics. 3rd ed. New York: McGraw-Hill Professional; 1996.
39. Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. *International Journal of Radiation Oncology Biology Physics* 2003; **56**: 1085 - 1092.
40. Chandan VS, Wolsh L. Postirradiation angiosarcoma of the prostate. *Archives of Pathology and Laboratory Medicine* 2003; **127**: 876 - 878.
41. Chen CC, Sheu RJ, Yeh CY, *et al.* A detailed study on the neutron contamination for a 10 MeV medical electron accelerator. *Nuclear Instruments and Methods in Physics Research A* 2006; **562**: 1033 - 1037.
42. Chibani O, Ma C-MC. Photonuclear dose calculations for high-energy photon beams for Siemens and Varian linacs. *Medical Physics* 2003; **30**: 1990 - 2000.
43. Chrouser K, Leibovich B, Zincke H, *et al.* Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. *Journal of Urology* 2005; **174**: 107 - 110.
44. Ciezki JP, Reddy CA, Garcia J, *et al.* PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. *International Journal of Radiation Oncology Biology Physics* 2006; **64**: 512 - 517.
45. Collie AC, Buskirk SJ, Wehle MJ, *et al.* Evaluation of chronic toxicity following radiation therapy for patients with a rising PSA status post prostatectomy. *International Journal of Radiation Oncology Biology Physics* 2004; **60**: S478.
46. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. *Journal of Clinical Oncology* 2005; **23**: 8146 - 8151.
47. Corner C, Rojas AM, Bryant L, *et al.* A phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2008; **72**: 441 - 446.

48. Cozzi L, Buffa FM, Fogliata A. Comparative analysis of dose volume histogram reduction algorithms for normal tissue complication probability calculations. *Acta Oncologica* 2000; **39**: 165 - 171.
49. Dale RG. The application of the linear-quadratic dose-effect equation of fractionated and protracted radiotherapy. *The British Journal of Radiology* 1985; **58**.
50. Dasu A. Is the α / β value for prostate tumours low enough to be safely used in clinical trials? *Clinical Oncology* 2007; **19**: 289 - 301.
51. Dasu A, Toma-Dasu I. Dose-effect models for risk-relationship to cell survival parameters. *Acta Oncologica* 2005; **44**: 829 - 835.
52. Dasu A, Toma-Dasu I, Olofsson J, *et al*. The use of risk estimation models for the induction of secondary cancers following radiotherapy. *Acta Oncologica* 2005; **44**: 339 - 347.
53. Dattori MJ, Wallner K, True L, *et al*. Long-term prostate cancer control (13 year actuarial) in patients with a high likelihood of extracapsular cancer extension using Pd-103 brachytherapy and supplemental beam radiation. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: S298.
54. Dearnaley DP, Khoo VS, Norman AR, *et al*. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomized trial. *The Lancet* 1999; **353**: 267 - 272.
55. Dearnaley DP, Khoo VS, Norman AR, *et al*. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. *The Lancet* 1999; **353**: 267 - 271.
56. Demanes DJ, Altieri GA, Brandt D, *et al*. Long term results of high dose rate brachytherapy and external beam with and without androgen suppression for prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: S38.
57. Demanes DJ, Gilhezan M, Schour L, *et al*. High dose rate brachytherapy (HDR-BT) as monotherapy for favorable prostate cancer: excellent 5-year control rates and low toxicity *International Journal of Radiation Oncology Biology Physics* 2008; **69**: S83.

58. Demanes JD, Rodriguez RR, Schour L, *et al.* High-dose rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. *International Journal of Radiation Oncology Biology Physics* 2005; **61**: 1306 - 1316.
59. DeMeerleer GO, Vakaet LAML, De Gerssem WRT, *et al.* Radiotherapy for prostate cancer with or without intensity modulated beams: a planning comparison. *International Journal of Radiation Oncology Biology Physics* 2000; **47**: 639 - 648.
60. d'Errico F, Nath R, Tana L, *et al.* In-phantom dosimetry and spectrometry of photoneutrons from an 18 MV linear accelerator. *Medical Physics* 1998; **25**: 1717 - 1724.
61. Dinges S, Deger S, Koswig S, *et al.* High-dose rate interstitial with external beam irradiation for localized prostate cancer – results of a prospective trial. *Radiotherapy and Oncology* 1998; **48**: 197 - 202.
62. Dorr W, Herrmann T. Second primary tumours after radiotherapy for malignancies. *Strahlentherapie und Onkologie* 2002; **178**: 357 - 362.
63. Dorr W, Herrmann T. Cancer induction by radiotherapy: dose dependence and spatial relationship to irradiated volume. *Journal of Radiological Protection* 2002; **22**: A117 - A121.
64. Dorr W, Herrmann T. Second tumors after oncologic treatment. *Strahlentherapie und Onkologie* 2008; **184**: 67 - 72.
65. Emami B, Lyman JT, Brown A, *et al.* Tolerance of normal tissue to therapeutic irradiation. *International Journal of Radiation Oncology Biology Physics* 1991; **21**: 109 - 122.
66. Eulau SM, van Hollebeke L, Cavanagh W, *et al.* High dose rate ¹⁹²Iridium brachytherapy in localized prostate cancer: Results and toxicity with maximum follow-up of 10 years. *International Journal of Radiation Oncology Biology Physics* 2000; **48**: S149.
67. Facure A, Falcao RC, Silva AXD, *et al.* A study of neutron spectra from medical linear accelerators. *Applied Radiation and Isotopes* 2005; **62**: 69 - 72.

68. Feigenberg SJ, Lee RW, Desilvio ML, *et al.* Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. *International Journal of Radiation Oncology Biology Physics* 2005; **62**: 956 - 964.

69. Fernandez F, Domingo C, Amgarou K, *et al.* Neutron measurements in a Varian 2100C linac facility using a Bonner sphere system based on passive gold activation detectors. *Radiation Protection Dosimetry* 2007; **126**: 361 - 365.

70. Fowler JF, Ritter MA, Chappel RJ, *et al.* What hypofractionated protocols should be tested for prostate cancer? *International Journal of Radiation Oncology Biology Physics* 2003; **56**: 1093 - 1104.

71. Galalae RM, Kovacs G, Schultze J, *et al.* Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2002; **52**: 81 - 90.

72. Galalae RM, Martinez A, Mate T, *et al.* Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2004; **58**: 1048 - 1055.

73. Gershkevitch E, Rosenberg I, Dearnaley PD, *et al.* Bone marrow doses and leukemia risk in radiotherapy of prostate cancer. *Radiotherapy and Oncology* 1999; **53**: 189 - 197.

74. Ghadjar P, Keller T, Rentsch CA, *et al.* Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. *Brachytherapy* 2009; **8**: 45 - 51.

75. Ghilezan M, Vargas C, Gustafson G, *et al.* Similar 5-year clinical outcome for high dose rate (HDR) and low dose rate (LDR) brachytherapy (BT) for early prostate cancer patients. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: S37.

76. Giovannucci E, Platz EA. Chapter 2: Epidemiology of prostate cancer. In: Vogelzang NJ, Scardino PT, Shipley WU, *et al.*, editors. *Comprehensive textbook of*

- genitourinary oncology. Philadelphia: Lippincott Williams & Wilkins; 2006.
77. Gray LH. Radiation biology and cancer. In: Cellular radiation biology: A symposium considering radiation effects in the cell and possible implications for cancer therapy. Baltimore: William & Wilkins; 1965. pp. 8 - 25.
 78. Gregori B, Papadopulos S, Cruzate J, *et al.* Multisphere neutron spectrometric system with thermoluminescence dosimeters: sensitive improvement. *Radiation Protection Dosimetry* 2002; **101**: 133 - 136.
 79. Grills IS, Martinez AA, Hollander M, *et al.* High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. *The Journal of Urology* 2004; **171**: 1098 - 1104.
 80. Hall EJ. Radiology for the radiologist. Philadelphia: Lippincott Williams & Wilkins; 2000.
 81. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. *International Journal of Radiation Oncology Biology Physics* 2006; **65**: 1 - 7.
 82. Hall EJ, Wu C-S. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. *International Journal of Radiation Oncology Biology Physics* 2003; **56**: 83 - 88.
 83. Hanks GE, Schultheiss TE, Hunt MA, *et al.* Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. *International Journal of Radiation Oncology Biology Physics* 1995; **31**: 25 - 29.
 84. Harrison RM. Second cancers following radiotherapy: a suggested common dosimetry framework for therapeutic and concomitant exposures. *The British Journal of Radiology* 2004; **77**: 986 - 990.
 85. Harrison RM, Wilkinson M, Shemilt A, *et al.* Organ doses from prostate radiotherapy and associated concomitant exposures. *The British Journal of Radiology* 2006; **79**: 487 - 496.
 86. Hartford AC, Gladstone DJ, Siegne JD, *et al.* First report on the clinical use of Palladium-103 coils: Safety and efficacy in the brachytherapy treatment of early stage prostate cancer. *International Journal of Radiation Oncology Biology Physics*

- 2005; **63**: S319 - S320.
87. Holmberg L, Bill-Axelsson A, Helgesen F, *et al.* A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. *The New England Journal of Medicine* 2002; **347**.
88. Horwitz EM, Vicini FA, Ziaja EL, *et al.* Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. *International Journal of Radiation Oncology Biology Physics* 1996; **36**: 565 - 571.
89. Howell RM, Ferenci MS, Hertel NE, *et al.* Calculation of effective dose from measurements of secondary neutron spectra and scattered photon dose from dynamic MLC IMRT for 6 MV, 15 MV, and 18 MV beam energies. *Medical Physics* 2006; **33**: 360 - 368.
90. Hsu IC, Pickett B, Shinohara K, *et al.* Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation. *International Journal of Radiation Oncology Biology Physics* 2000; **46**: 851 - 858.
91. Huang WL, Li QF, Lin YZ. Calculation of photoneutrons produced in the targets of electron linear accelerators for radiography and radiotherapy applications. *Nuclear Instruments and Methods in Physics Research B* 2005; **229**: 339 - 347.
92. Huguenin PU, Bitterli M, Lutolf UM, *et al.* Localized prostate cancer in elderly patients. *Strahlentherapie und Onkologie* 1999; **175**: 554 - 558.
93. ICRP. ICRP Publication 98: Radiation safety aspects of brachytherapy for prostate cancer using permanently implanted sources. In: Valentin J, editor. *Annals of the ICRP*. Vol 35: International Commission on radiological Protection; 2005. pp. 37 - 38.
94. ICRU. ICRU Report 13. Neutron fluence, neutron spectra and kerma. In: ICRU, editor. Washington, D.C.: International Commission on Radiation Units and Measurements; 1969.

95. Itoh M, Yamada Y, Kiriyama N, *et al.* Neutron activation analysis of low level lithium in water samples. *Journal of Radioanalytical and Nuclear Chemistry* 1993; **172**: 289 - 298.
96. Jackson A, Kutcher GJ, Yorke ED. Probability of radiation-induced complications for normal-tissues with parallel architecture subject to nonuniform irradiation. *Medical Physics* 1993; **20**: 613 - 625.
97. Jani AB, Hellman S. Early prostate cancer: clinical decision-making. *The Lancet* 2003; **361**: 1045 - 1053.
98. Jaradat AK, Biggs PJ. Measurement of the neutron leakage from a dedicated intraoperative radiation therapy electron linear accelerator and a conventional linear accelerator. *Medical Physics* 2008; **35**: 1711 - 1717.
99. Jones B, Dale RG, Deehan C, *et al.* The role of biologically effective dose (BED) in clinical oncology. *Clinical Oncology* 2001; **13**: 71 - 81.
100. Kallman P, Agren A, Brahme A. Tumour and normal tissue responses to fractionated non-uniform dose delivery. *International Journal of Radiation Biology* 1992; **62**: 249 - 262.
101. Karlsdottir A, Johannessen DC, Muren LP, *et al.* Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. *Radiotherapy and Oncology* 2004; **71**: 43 - 53.
102. Khoo VS. The clinical management of prostate cancer - The radiation oncologist's approach and outcomes. In: Abel PD, Lalani E-N, editors. Prostate cancer: Clinical and scientific aspects - Bridging the gap. London: Imperial College Press; 2003. pp. 853 - 909.
103. King CR. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models. *Brachytherapy* 2002; **1**: 219 - 226.
104. King CR, DiPetrillo TA, Wazer DE. Optimal radiotherapy for prostate cancer: Predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models. *International Journal of Radiation Oncology Biology Physics* 2000; **46**: 165 - 172.

105. Kleinerman RA, Liebermann JV, Li FP. Second cancer following cancer of the male genital system in Connecticut, 1935 - 82. *National Cancer Institute Monograph* 1985; **68**: 139 - 147.
106. Kollmeier MA, Stock RG, Stone NN. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality. *International Journal of Radiation Oncology Biology Physics* 2003; **57**: 645 - 653.
107. Kry SF, Followill D, White RA, *et al.* Uncertainty of calculated risk estimates for secondary malignancies after radiotherapy. *International Journal of Radiation Oncology Biology Physics* 2007; **68**: 1265 - 1271.
108. Kry SF, Price M, Followill D, *et al.* The use of LiF (TLD-100) as an out-of-field dosimeter. *Journal of Applied Clinical Medical Physics* 2007; **8**: 169 - 175.
109. Kry SF, Salehpour M, Followill DS, *et al.* Out-of-field photon and neutron dose equivalents from step-and-shoot intensity-modulated radiation therapy. *International Journal of Radiation Oncology Biology Physics* 2005; **62**: 1204 - 1216.
110. Kuban D, Pollack A, Huang E, *et al.* Hazards of dose escalation in prostate cancer radiotherapy. *International Journal of Radiation Oncology Biology Physics* 2003; **57**: 1260 - 1268.
111. Kuban DA, Tucker SL, Dong L, *et al.* Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2008; **70**: 67 - 74.
112. Kupelian PA, Thakkar VV, Khuntia D, *et al.* Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: 1463 - 1468.
113. Kutcher GJ, Burman CM. Calculation of complication probability factors for non-uniform normal tissue irradiation: The effective volume method. *International Journal of Radiation Oncology Biology Physics* 1989; **16**: 1623 - 1630.
114. Kwa SLS, Lebesque JV, Theuws JCM, *et al.* Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. *International Journal of*

- Radiation Oncology Biology Physics* 1998; **42**: 1 - 9.
115. Landauer. Luxel+ dosimeter for X, gamma, beta, and neutron radiation. IL, USA: Landauer, Inc.; 2005.
 116. Lanzl LH. The Rando phantom and its medical applications. Chicago, Illinois: The Phantom Laboratory; 1995.
 117. Lee RW, DeGuzman AF, McMullen KP, *et al.* Dosimetry and cancer control after low-dose-rate prostate brachytherapy. *International Journal of Radiation Oncology Biology Physics* 2005; **61**: 52 - 59.
 118. Lee RW, Desilvio ML, Lawton C, *et al.* A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: Preliminary results of RTOG P-0019. *International Journal of Radiation Oncology Biology Physics* 2006; **64**: 804 - 809.
 119. Lee T-K, Allison RR, O'Brien KF, *et al.* Lymphocyte radiosensitivity correlated with pelvic radiotherapy morbidity. *International Journal of Radiation Oncology Biology Physics* 2003; **57**: 222 - 229.
 120. Levi F, Randimbison L, Te V-C, *et al.* Second primary tumors after prostate carcinoma. *Cancer* 1999; **86**: 1567 - 1570.
 121. Li AX, Wang JZ, Stewart RD, *et al.* Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations. *Physics in Medicine and Biology* 2003; **48**: 2753 - 2765.
 122. Liauw SL, Sylvester JE, Morris CG, *et al.* Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. *International Journal of Radiation Oncology Biology Physics* 2006; **66**: 669 - 673.
 123. Limbacher AL, Ghilezan M, Gustafson G, *et al.* Impact of age on biochemical control in a cohort of intermediate- and high-risk prostate cancer patients treated with high-dose-rate brachytherapy boost combined with pelvic external beam radiation

- therapy *Brachytherapy* 2009; **8**: 174.
124. Lin J-P, Chu T-C, Lin S-Y, *et al.* The measurement of photoneutrons in the vicinity of a Siemens Primus linear accelerator. *Applied Radiation and Isotopes* 2001; **55**: 315 - 321.
 125. Liu JC, Kase KR, Mao XS, *et al.* Calculations of photoneutrons from Varian Clinac accelerators and their transmissions in materials. *Radiation Dosimetry and Safety*. Taipei, Taiwan: SLAC National Accelerator Laboratory; 1997. pp. 1 - 5.
 126. Livsey JE, Cowan RA, Wylie JP, *et al.* Hypofractionated conformal radiotherapy in carcinoma of the prostate: Five-year outcome analysis. *International Journal of Radiation Oncology Biology Physics* 2003; **57**: 1254 - 1259.
 127. Luxton G, Hancock SL, Boyer AL. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. *International Journal of Radiation Oncology Biology Physics* 2004; **59**: 267 - 284.
 128. Luxton G, Keall PJ, King CR. A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD). *Physics in Medicine and Biology* 2008; **53**: 23 - 36.
 129. Lyman JT. Complication probability as assessed from dose-volume-histogram. *Radiation Research* 1985; **104**: S13 - S19.
 130. Lyman JT, Wolbarst AB. Optimization of radiation therapy, III: a method of assessing complication probabilities from dose-volume histograms. *International Journal of Radiation Oncology Biology Physics* 1987; **13**: 103 - 109.
 131. MacKay RI, Hendry JH, Moore CJ, *et al.* Predicting late rectal complications following prostate conformal radiotherapy using biologically effective doses and normalized dose-surface histograms. *The British Journal of Radiology* 1997; **70**: 517 - 526.
 132. Madsen B, Pham H, Hsi RA, *et al.* Comparison of rectal dose volume histograms for definitive prostate radiotherapy among stereotactic radiotherapy, IMRT, and 3D-CRT techniques. *International Journal of Radiation Oncology Biology Physics* 2004; **60**: S633.
 133. Mahadevan A, Reddy C, Ciezki JP, *et al.* The prognostic significance of PSA at 6

- months after external beam radiation for prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2004; **60**: S459.
134. Mangar SA, Huddart RA, Parker CC, *et al.* Technological advances in radiotherapy for the treatment of localised prostate cancer. *European Journal of Cancer* 2005; **41**: 908 - 921.
135. Marcu L, Quach K. The role of post-implant dosimetry in the quality assessment of prostate implants. *Australian Physical & Engineering Sciences in Medicine* 2006; **29**: 310 - 314.
136. Mark R, Vallabhan G, Akins A, *et al.* Interstitial high dose rate (HDR) brachytherapy for early stage prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: S304.
137. Mark RJ, Anderson PJ, Neumann TR, *et al.* Interstitial high dose rate (HDR) brachytherapy as monotherapy for early stage prostate cancer: a report of 254 cases *International Journal of Radiation Oncology Biology Physics* 2008; **72**: S133.
138. Martin T, Baltas D, Kurek R, *et al.* 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. *Strahlentherapie und Onkologie* 2004; **180**: 225 - 232.
139. Martinez A, Yan D, Brabbins D, *et al.* Dose escalation in prostate cancer: A comparison of RTOG chronic toxicities for patients treated in the adaptive external beam process with 3D-conformal or IMRT vs. external beam plus conformal HDR brachytherapy boost. *International Journal of Radiation Oncology Biology Physics* 2002; **54**: S108 - S109.
140. Martinez AA, Demanes DJ, Galalae R, *et al.* Ten-year results in 1577 intermediate/high risk prostate cancer patients treated with external beam radiation therapy and hypofractionated high-dose-rate brachytherapy boost *Brachytherapy* 2009; **8**: 109.
141. Martinez AA, Pataki I, Edmundson G, *et al.* Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report. *International Journal of Radiation Oncology Biology Physics* 2001; **49**: 61 - 69.

142. Mayer S, Otto T, Golnik N. Determination of the photon-contribution of a ^{238}Pu -Be source. *Nuclear Instruments and Methods in Physics Research B* 2004; **213**: 214 - 217.
143. McCredie M, Macfarlane GJ, Stewart J, *et al.* Second primary cancer following cancers of kidney and prostate in New South Wales (Australia), 1972 - 91. *Cancer Causes and Control* 1996; **7**: 337 - 344.
144. McElveen TL, Waterman FM, Kim H, *et al.* Factors predicting for urinary incontinence after prostate brachytherapy. *International Journal of Radiation Oncology Biology Physics* 2004; **59**: 1395 - 1404.
145. McKeever SWS, Moskovitch M, Townsend PD. Thermoluminescence dosimetry materials: properties and uses. Kent, England: Nuclear Technology Publishing; 1995.
146. Merrick GS, Butler WM, Wallner KE, *et al.* Erectile function after prostate brachytherapy. *International Journal of Radiation Oncology Biology Physics* 2005; **62**: 437 - 447.
147. Merrick GS, Wallner KE, Butler WM. Minimizing prostate brachytherapy-related morbidity. *Urology* 2003; **62**: 786 - 792.
148. Michalski JM, Kong FM, Mansur DB, *et al.* Quality of life following 3D conformal radiation therapy or permanent interstitial brachytherapy for localized prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2001; **51**: S99.
149. Millar JL, Zwahlen DR, Andrianopoulos N, *et al.* Improved prostate cancer control with the use of HDR brachytherapy boost *Brachytherapy* 2008; **7**: 120.
150. Miller DC, Montie JE. Chapter 10: Staging systems for prostate cancer. In: Vogelzang NJ, Scardino PT, Shipley WU, *et al.*, editors. *Comprehensive textbook of genitourinary oncology*. Philadelphia: Lippincott Williams & Wilkins; 2006.
151. Miller VA, Reuter V, Scher HI. Primary squamous cell carcinoma of the prostate after radiation seed implantation for adenocarcinoma. *Urology* 1995; **46**: 111 - 113.
152. Mohammadi M. EPID dosimetry in intensity modulated radiation therapy applications. School of Chemistry and Physics. Vol Ph.D. Adelaide: University of

- Adelaide; 2006.
153. Mohan DS, Kupelian PA, Willoughby TR. Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland. *International Journal of Radiation Oncology Biology Physics* 2000; **46**: 575 - 580.
 154. Moon K, Stukenberg GJ, Keim J, *et al.* Cancer incidence after localized therapy for prostate cancer. *Cancer* 2006; **107**: 991 - 998.
 155. Moss WT, Brand WN, Battifora H. The prostate gland. In: Radiation oncology: rationale, technique, results. Saint Louis: The C.V. Mosby; 1973.
 156. Movsas B, Hanlon AL, Pinover W, *et al.* Is there an increased risk of second primaries following prostate irradiation? *International Journal of Radiation Oncology Biology Physics* 1998; **41** 251 - 255.
 157. Moyers MF, Benton ER, Ghebremedhin A, *et al.* Leakage and scatter radiation from a double scattering based proton beamline. *Medical Physics* 2008; **35**: 128 - 144.
 158. Muller A-C, Ganswindt U, Bamberg M, *et al.* Risk of second malignancies after prostate irradiation? *Strahlentherapie und Onkologie* 2007; **183**: 605 - 609.
 159. Nag S, Gupta N. A simple method of obtaining equivalent doses for use in HDR brachytherapy. *International Journal of Radiation Oncology Biology Physics* 2000; **46**: 507 - 513.
 160. Narayana V, Troyer S, Evans V, *et al.* Randomized trial of high- and low-source strength ¹²⁵I prostate seed implants. *International Journal of Radiation Oncology Biology Physics* 2005; **61**: 44 - 51.
 161. Neugut AI, Ahsan H, Robinson E, *et al.* Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. *Cancer* 1997; **79**: 1600 - 1604.
 162. Neumann T, Mark R, Akins A, *et al.* Interstitial high dose rate (HDR) brachytherapy + IMRT vs. HDR monotherapy for early stage prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: S313 - S314.
 163. Niemierko A, Goitein M. Calculation of normal tissue complication probability and

- dose-volume histogram reduction schemes for tissues with a critical element architecture. *Radiotherapy and Oncology* 1991; **20**: 166 - 176.
164. Niemierko A, Goitein M. Implementation of a model for estimating tumor control probability for an inhomogeneously irradiated tumor *Radiotherapy and Oncology* 1993; **29**: 140 - 147.
165. Niemierko A, Goitein M. Modeling of normal tissue response to radiation: the critical volume model. *International Journal of Radiation Oncology Biology Physics* 1993; **25**: 135 - 145.
166. Nilson S, Norlén BJ, Wildmark A. A systematic overview of radiation therapy effects in prostate cancer. *Acta Oncologica* 2004; **43**: 316 - 381.
167. NRC. Technical manual for AN/PDR-70 (Snoopy NP-2) neutron survey meter. Connecticut: Canberra Industries, Inc.; 2003.
168. Obryk B, Bilski P, Budzanowski M, *et al.* The response of different types of TL lithium fluoride detectors to high-energy mixed radiation fields. *Radiation Measurements* 2008; **43**: 1144 - 1148.
169. Ongaro C, Zanini A, Nastasi U, *et al.* Analysis of photoneutron spectra produced in medical accelerators. *Physics in Medicine and Biology* 2000; **45**: L55 - L61.
170. Oster L, Horowitz YS, Horowitz A. Glow curve readout of LiF:Mg,Cu,P (GR-200) chips at maximum temperatures between 240 °C and 280 °C: elimination of the residual signal. *Radiation Protection Dosimetry* 1993; **49**: 407 - 411.
171. Osterlind A, Rorth M, Prener A. Second cancer following cancer of the male genital system in Denmark, 1943 - 80. *National Cancer Institute Monograph* 1985; **68**: 341 - 347.
172. Pawlish KS, Schottenfeld D, Severson R, *et al.* Risk of multiple primary cancers in prostate cancer patients in the Detroit metropolitan area: a retrospective cohort study. *The Prostate* 1997; **33**: 75 - 86.
173. Perez CA, Michalski JM, Purdy JA, *et al.* Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: Preliminary results of a nonrandomized comparison. *International Journal of Radiation Oncology Biology*

- Physics* 2000; **47**: 629 - 637.
174. Peschel RE, Chen Z, Roberts K, *et al.* Long-term Complications with prostate implants: Iodine-125 vs. Palladium-103. *Radiation Oncology Investigations* 1999; **7**: 278 - 288.
 175. Peters CA, Smith MJ, Stone NN, *et al.* Prostate brachytherapy in twenty-four patients with inflammatory bowel disease. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: S298.
 176. Phan TP, Puthawala A, Sharma A, *et al.* Treatment of localized prostate cancer with external beam radiation therapy and high dose rate interstitial brachytherapy. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: S315 - S316.
 177. Pickles T, Phillips N. The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984 - 2000. *Radiotherapy and Oncology* 2002; **65**: 145 - 151.
 178. Pollack A, Hanlon AL, Horwitz EM, *et al.* Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. *International Journal of Radiation Oncology Biology Physics* 2006; **64**: 518 - 526.
 179. Pollack A, Smith LG, von Eschenbach AC. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. *International Journal of Radiation Oncology Biology Physics* 2000; **48**: 507 - 512.
 180. Pollack A, Zagars GK, Starkschall G, *et al.* Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. *International Journal of Radiation Oncology Biology Physics* 2002; **53**: 1097 - 1105.
 181. Potters L, Morgenstern C, Mullen EE, *et al.* Twelve year outcomes following permanent brachytherapy in patients with clinically localized prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2004; **60**: S183 - S184.
 182. Pradhan AS, Bhatt RC. Thermoluminescence response of LiF:Mg,Cu,P and LiF TLD-100 to thermal neutrons, ²⁴¹Am Alphas and gamma rays. *Radiation Protection*

- Dosimetry* 1989; **27**: 185 - 188.
183. Purdy JA. Dose to normal tissues outside the radiation therapy patient's treated volume: a review of different radiation therapy techniques. *Health Physics* 2008; **95**: 666 - 676.
184. Raben A, Grebler A, Ivker RA, *et al.* Patterns and predictors of acute toxicity after HDR brachytherapy and 3D-CRT for localized prostate cancer: Preliminary results of phase I-II dose escalation study. *International Journal of Radiation Oncology Biology Physics* 2001; **51**: S302.
185. Ralston AC. An in vivo neutron activation analysis system for cadmium in the human liver and kidney: construction, optimization and calibration. School of Natural and Built Environments. Vol Master of Applied Science (Applied Physics). Adelaide: University of South Australia; 1994.
186. Rancati T, Fiorino C, Gagliardi G, *et al.* Early clinical and radiological pulmonary complications following breast cancer radiation therapy: NTCP fit with four different models. *Radiotherapy and Oncology* 2007; **82**: 308 - 316.
187. Ray ME, Thames HD, Levy LB, *et al.* PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. *International Journal of Radiation Oncology Biology Physics* 2006; **64**: 1140 - 1150.
188. Rebello WF, Silva AX, Facure A. Multileaf shielding design against neutrons produced by medical linear accelerator. *Radiation Protection Dosimetry* 2008; **128**: 227 - 233.
189. Reft CS, Runkel-Muller R, Myriantopoulos L. In vivo and phantom measurements of the secondary photon and neutron doses for prostate patients undergoing 18 MV IMRT. *Medical Physics* 2006; **33**: 3734 - 3742.
190. Rheingold SR, Neugut AI, Meadows AT. Secondary cancers: incidence, risk factors, and management. *Complications of cancer and its treatment*. Vol 2006. Atlanta: American Cancer Society; 2003.
191. Ron E. Ionizing radiation and cancer risk: evidence and epidemiology. *Radiation Research* 1998; **150**: S30 - S41.

192. Ruben JD, Davis S, Evans C, *et al.* The effect of intensity-modulated radiotherapy on radiation-induced second malignancies. *International Journal of Radiation Oncology Biology Physics* 2008; **70**: 1530 - 1536.
193. Sanchez-Nieto B, Nahum AE. BIOPLAN: Software for the biological evaluation of radiotherapy treatment plans. *Medical Dosimetry* 2000; **25**: 71 - 76.
194. Sandler HM, Michalski JM. Chapter 13F: 3D conformal radiotherapy for localized prostate cancer. In: Vogelzang NJ, Scardino PT, Shipley WU, *et al.*, editors. *Comprehensive textbook of genitourinary oncology*. Philadelphia: Lippincott Williams & Wilkins; 2006.
195. Schmitt HW, Block RC, Bailey RL. Total neutron cross section of B¹⁰ in the thermal neutron energy range. *Nuclear Physics* 1960; **17**: 109 - 115.
196. Schneider U, Zwahlen D, Ross D, *et al.* Estimation of radiation-induced cancer from three-dimensional dose distributions: concept of organ equivalent dose. *International Journal of Radiation Oncology Biology Physics* 2005; **61**: 1510 - 1515.
197. Schultheiss TE, Orton CG, Peck RA. Models in radiotherapy: Volume effects. *Medical Physics* 1983; **10**: 410 - 415.
198. Semenenko VA, Li XA. Lyman-Kutcher-Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data. *Physics in Medicine and Biology* 2008; **53**: 737 - 755.
199. Shah JN, Ennis RD. Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: Use of a comprehensive toxicity scoring system and identification of rectal dosimetric toxicity predictors. *International Journal of Radiation Oncology Biology Physics* 2006; **64**: 817 - 824.
200. Shahar KH, McGary JE, Mai W, *et al.* Retrospective analysis of late rectal bleeding in prostate cancer patients treated with intensity-modulated radiotherapy (IMRT). *International Journal of Radiation Oncology Biology Physics* 2004; **60**: S459.
201. Shipley WU, Scardino PT, Kaufman DS, *et al.* Chapter 13A: Advising patients with early prostate cancer on their treatment decision. In: Vogelzang NJ, Scardino PT,

- Shiple WU, *et al.*, editors. Comprehensive textbook of genitourinary oncology. Philadelphia: Lippincott Williams & Wilkins; 2006.
202. Shirato H, Mizuta M, Miyasaka K. A mathematical model of the volume effect which postulates cell migration from unirradiated tissues. *Radiotherapy and Oncology* 1995; **35**: 227 - 231.
203. Soto DE, Kempien D, Schipper M, *et al.* Pelvic field size and biochemical failure in the treatment of prostate cancer: a single institution experience. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: S323 - S324.
204. Springer CD, Boyd RN, Elsdon TC, *et al.* Outcome analysis of HDR prostate brachytherapy in the management of patients with localized prostate cancer in a community cancer center. *Brachytherapy* 2007; **6**: 106.
205. Stavrev P, Stavreva N, Niemierko A, *et al.* Generalization of the normalized dose-response gradient to non-uniform dose delivery. *Physics in Medicine and Biology* 2001; **46**: 1501 - 1518.
206. Stavreva N, Stavrev P, Brahme A. Some limitations of the application of the NTCP model describing the response of organs with 'relatively serial' structure. *International Journal of Radiation Biology* 2002; **78**: 948 - 952.
207. Steineck G, Helgesen F, Adolfsson J, *et al.* Quality of life after radical prostatectomy or watchful waiting. *The New England Journal of Medicine* 2002; **347**: 790 - 796.
208. Stock RG, Cahlon O, Cesaretti JA, *et al.* Combined modality treatment in the management of high-risk prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2004; **59**: 1352 - 1359.
209. Stock RG, Cesaretti JA, Stone NN. Disease-specific survival following the brachytherapy management of prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2006; **64**: 810 - 816.
210. Stock RG, Kollmeier M, Stone NN. Biochemical outcomes following hormonal therapy, Pd-103 prostate brachytherapy and 3D conformal external beam

- irradiation in the treatment of high risk prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2002; **54**: S271.
211. Storey MR, Pollack A, Zagars G, *et al.* Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. *International Journal of Radiation Oncology Biology Physics* 2000; **48**: 635 - 642.
212. Suen AW, Ghilezan M, Mohammed N, *et al.* Does brachytherapy reduce morbidity compared to external beam adaptive radiotherapy or pelvic irradiation with brachytherapy boost for localized prostate cancer? *Brachytherapy* 2008; **7**: 118.
213. Sunil C, Sarkar PK. Empirical estimation of photoneutron energy distribution in high-energy electron accelerators. *Nuclear Instruments and Methods in Physics Research A* 2007; **581**: 844 - 849.
214. Sylvester JE. High-dose-rate versus low-dose-rate monotherapy in the treatment of localized prostate cancer: The case for high-dose-rate monotherapy: an up and coming treatment option for low-risk prostate cancer *Brachytherapy* 2006; **5**: 1 - 4.
215. Takam R, Bezak E, Yeoh EE. Risk of second primary cancer following prostate cancer radiotherapy: DVH analysis using the competitive risk model. *Physics in Medicine and Biology* 2009; **54**: 611-625.
216. Tanner RJ, Bartlett DT, Hager LG. Operational and dosimetric characteristics of etched-track neutron detectors in routine neutron radiation protection dosimetry. *Radiation Measurements* 2005; **40**: 549 - 559.
217. Taussky D, Toi A, McLean M, *et al.* Sequential evaluation of prostate edema following permanent seed prostate brachytherapy using CT-MRI fusion. *International Journal of Radiation Oncology Biology Physics* 2004; **60**: S456.
218. Teh BS, Mai W, Huang E, *et al.* Late gastrointestinal (GI) and genitourinary (GU) toxicity following intensity-modulated radiation therapy (IMRT) for prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2001; **51**: S310 - S311.
219. Teslow TN, Ahmad S, Uy NW, *et al.* Comparison of tumor control probability and normal tissue complication probability between 3D-CRT and IMRT plans in patients with prostate cancer. *European Journal of Cancer* 2001; **37**: S204

- S205.
220. Thakkar VV, Khuntia D, Reddy C, *et al.* Hypofractionated intensity modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcome results. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: S124 - S125.
221. Thames HD, Zhang M, Tucker SL, *et al.* Cluster models of dose - volume effects. *International Journal of Radiation Oncology Biology Physics* 2004; **59**: 1491 - 1504.
222. Thellenberg C, Malmer B, Tavelin B, *et al.* Second primary cancers in men with prostate cancer: An increased risk of male breast cancer. *The Journal of Urology* 2003; **169**: 1345 - 1348.
223. Tran A, Wallner K, Merrick G, *et al.* Rectal fistulas after prostate brachytherapy. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: 150 - 154.
224. Travis LB. The epidemiology of second primary cancers. *Cancer Epidemiology, Biomarkers & Prevention* 2006; **15**: 2020 - 2026.
225. Tripathy SP, Bakshi AK, Sathian V, *et al.* Measurement of ²⁴¹Am-Be spectra (bare and Pb-covered) using TLD pairs in multi-spheres: spectrum unfolding by different methods. *Nuclear Instruments and Methods in Physics Research A* 2009; **598**: 556 - 560.
226. van Dyk J. The modern technology of radiation oncology: A compendium for medical physicists and radiation oncologists Wisconsin: Medical Physics Publishing; 1999.
227. Vanhavere F, Huyskens D, Struelens L. Peripheral neutron and gamma doses in radiotherapy with an 18 MV linear accelerator. *Radiation Protection Dosimetry* 2004; **110**: 607 - 612.
228. Verellen D, Vanhavere F. Risk assessment of radiation-induced malignancies based on whole-body equivalent dose estimates for IMRT treatment in the head and neck region. *Radiotherapy and Oncology* 1999; **53**: 199 - 203.
229. Vicini F, Vargas C, Gustafson G, *et al.* High dose rate brachytherapy in the treatment

- of prostate cancer. *World Journal of Urology* 2003; **21**: 220 - 228.
230. Virtanen A, Pukkala E, Auvinen A. Incidence of bone and soft tissue sarcoma after radiotherapy: A cohort study of 295,712 Finnish cancer patients. *International Journal of Cancer* 2006; **118**: 1017 - 1021.
231. Waller EJ, Jamieson TJ, Cole D, *et al.* Experimental and computational determination of neutron dose equivalent around radiotherapy accelerators. *Radiation Protection Dosimetry* 2003; **107**: 225 - 232.
232. Wallner K, Merrick G, Sutlief S, *et al.* High-dose regions versus likelihood of cure after prostate brachytherapy. *International Journal of Radiation Oncology Biology Physics* 2005; **62**: 170 - 174.
233. Wallner K, Merrick G, True L, *et al.* ^{125}I versus ^{103}Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. *International Journal of Radiation Oncology Biology Physics* 2003; **57**: 1297 - 1303.
234. Wang B, Xu XG. Measurements of non-target organ doses using MOSFET dosimeters for selected IMRT and 3D-CRT radiation treatment procedures. *Radiation Protection Dosimetry* 2008; **128**: 336 - 342.
235. Warkentin B, Stavrev P, Stavreva N, *et al.* A TCP-NTCP estimation module using DVHs and known radiobiological models and parameter sets. *Journal of Applied Clinical Medical Physics* 2004; **5**: 50 - 63.
236. Waterman FM, Dicker AP. Probability of late rectal morbidity in ^{125}I prostate brachytherapy. *International Journal of Radiation Oncology Biology Physics* 2003; **55**: 342 - 353.
237. Withers HR, Taylor JMG, Maciejewski B. Treatment volume and tissue tolerance. *International Journal of Radiation Oncology Biology Physics* 1988; **14**: 751 - 759.
238. Wust P, von Borczyskowski DW, Henkel T, *et al.* Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy. *Radiotherapy and Oncology* 2004; **73**: 39 - 48.
239. Xu XG, Bednarz B, Paganetti H. A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction. *Physics in Medicine*

- and Biology* 2008; **53**: R193 - R241.
240. Yeoh EE, Fraser RJ, McGowan RE, *et al.* Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a phase III randomized trial *International Journal of Radiation Oncology Biology Physics* 2003; **55**: 943 - 955.
241. Yeoh EE, Holloway RH, Fraser RJ, *et al.* Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. *International Journal of Radiation Oncology Biology Physics* 2006; **66**: 1072 - 1083.
242. Yogeswaren ST, Teh BS, Mai W, *et al.* Radiation dose to testicles and serum testosterone levels in low risk prostate cancer patients undergoing intensity-modulated radiation therapy (IMRT). *International Journal of Radiation Oncology Biology Physics* 2004; **60**: S456.
243. Yorke ED, Kutcher GJ, Jackson A, *et al.* Probability of radiation-induced complications in normal tissues with parallel architecture under conditions of uniform whole or partial organ irradiation. *Radiotherapy and Oncology* 1993; **26**: 226 - 237.
244. Yoshioka Y, Nose T, Yoshida K, *et al.* High-dose-rate brachytherapy as monotherapy for localized prostate cancer: A retrospective analysis with special focus on tolerance and chronic toxicity. *International Journal of Radiation Oncology Biology Physics* 2003; **56**: 213 - 220.
245. Yurdakul G, de Reijke TM, Blank LECM, *et al.* Rectal squamous cell carcinoma 11 years after brachytherapy for carcinoma of the prostate. *The Journal of Urology* 2003; **169**: 280.
246. Zaider M, Zelefsky MJ, Cohen GN, *et al.* Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer. *International Journal of Radiation Oncology Biology Physics* 2005; **61**: 702 - 713.
247. Zanini A, Durisi E, Fasolo F, *et al.* Monte Carlo simulation of the photoneutron field in linac radiotherapy treatments with different collimation systems. *Physics in*

- Medicine and Biology* 2004; **49**: 571 - 582.
248. Zelefsky M, Kuban DA, Levy L, *et al.* Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with permanent brachytherapy. *International Journal of Radiation Oncology Biology Physics* 2005; **63**: S33 - S34.
249. Zelefsky MJ, Fuks Z, Happersett L, *et al.* Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. *Radiotherapy and Oncology* 2000; **55**: 241 - 249.
250. Zelefsky MJ, Lee WR. Chapter 13H: Brachytherapy. In: Vogelzang NJ, Scardino PT, Shipley WU, *et al.*, editors. *Comprehensive textbook of genitourinary oncology*. Philadelphia: Lippincott Williams & Wilkins; 2006.
251. Zelefsky MJ, Valicenti RK, Goodman K, *et al.* Chapter 58 Prostate Cancer. In: Perez CA, Brady LW, Halperin EC, *et al.*, editors. *Principles and practice of radiation oncology*. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004.
252. Zeller JL, Lynn C, Glass RM. Grading of prostate cancer. *The Journal of the American Medical Association* 2007; **298**: 1596.
253. Zietman AL, DeSilvio ML, Slater JD, *et al.* Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial *The Journal of the American Medical Association* 2005; **294**: 1233 - 1239.

